Eiger BioPharmaceuticals to Present at Jefferies Virtual Healthcare Conference 2021

Rhea-AI Summary

Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR) announced that CEO David Cory will present a corporate update at the Jefferies Virtual Healthcare Conference on June 2, 2021, at 4:00 PM EDT. A live webcast will be available on Eiger's website, with a replay accessible one hour after the event. Eiger specializes in targeted therapies for rare diseases, with key programs focusing on Hepatitis Delta Virus and its FDA-approved product, Zokinvy^®, for Hutchinson-Gilford Progeria Syndrome. The company will also conduct virtual one-on-one meetings with investors.

PALO ALTO, Calif., May 26, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that David Cory, President and Chief Executive Officer, will present a corporate update at the Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021 at 4:00 PM EDT.

A live webcast of the presentation will be available on the Eiger BioPharmaceuticals website at www.eigerbio.com under the "Investors" tab.  A replay of the webcast will be available approximately one hour following the completion of the live event.

Eiger will also host virtual one-on-one meetings with investors.

About Eiger 
Eiger is a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases.

Eiger's lead clinical programs are focused on the development of foundational therapies for Hepatitis Delta Virus (HDV) infection, the most serious form of viral hepatitis, with two complementary HDV treatments.  Lonafarnib is a first-in-class, oral prenylation inhibitor in a global Phase 3 trial.  Peginterferon lambda is a first-in-class, well-tolerated type III interferon entering Phase 3.

Zokinvy^® for the treatment of Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) and processing-deficient progeroid laminopathies is the Company's first FDA approved product.  A Marketing Authorization Application (MAA) is under review by the European Medicines Agency (EMA).

For additional information about Eiger and its clinical programs, please visit www.eigerbio.com.

Investors and Media:
Sri Ryali
Chief Financial Officer
Email: sryali@eigerbio.com 
Phone: 1-650-272-6138

View original content to download multimedia:http://www.prnewswire.com/news-releases/eiger-biopharmaceuticals-to-present-at-jefferies-virtual-healthcare-conference-2021-301300252.html

SOURCE Eiger BioPharmaceuticals, Inc.

FAQ

When is Eiger BioPharmaceuticals presenting at the Jefferies Virtual Healthcare Conference?

Eiger BioPharmaceuticals will present at the Jefferies Virtual Healthcare Conference on June 2, 2021, at 4:00 PM EDT.

Where can I watch the Eiger BioPharmaceuticals presentation live?

The live presentation by Eiger BioPharmaceuticals can be viewed on their website under the 'Investors' tab.

What is the focus of Eiger BioPharmaceuticals' clinical programs?

Eiger BioPharmaceuticals focuses on targeted therapies for serious rare diseases, primarily Hepatitis Delta Virus and Hutchinson-Gilford Progeria Syndrome.

What products does Eiger BioPharmaceuticals have in development?

Eiger's lead products include Lonafarnib for Hepatitis Delta Virus and Zokinvy^® for Hutchinson-Gilford Progeria Syndrome.

Is Eiger BioPharmaceuticals hosting investor meetings?

Yes, Eiger BioPharmaceuticals will host virtual one-on-one meetings with investors following the conference presentation.